Rehmann Capital Advisory Group Purchases 311 Shares of Boston Scientific Corporation $BSX

Rehmann Capital Advisory Group boosted its position in Boston Scientific Corporation (NYSE:BSX) by 5.6% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,878 shares of the medical equipment provider’s stock after purchasing an additional 311 shares during the quarter. Rehmann Capital Advisory Group’s holdings in Boston Scientific were worth $631,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Sound Income Strategies LLC raised its holdings in Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 120 shares in the last quarter. 1248 Management LLC bought a new position in Boston Scientific in the first quarter worth about $26,000. Y.D. More Investments Ltd bought a new position in Boston Scientific in the first quarter worth about $27,000. Princeton Global Asset Management LLC bought a new position in Boston Scientific in the second quarter worth about $32,000. Finally, Oliver Lagore Vanvalin Investment Group bought a new position in Boston Scientific in the second quarter worth about $37,000. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $102.42 on Friday. The business’s 50 day moving average price is $101.18 and its 200 day moving average price is $101.92. The firm has a market cap of $151.75 billion, a P/E ratio of 54.77, a P/E/G ratio of 2.45 and a beta of 0.61. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. The firm had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.Boston Scientific’s revenue for the quarter was up 20.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. On average, sell-side analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Activity at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total value of $4,923,500.00. Following the sale, the executive vice president owned 178,342 shares in the company, valued at $17,561,336.74. This represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Yoshiaki Fujimori sold 2,901 shares of the company’s stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the sale, the director owned 2,081 shares in the company, valued at approximately $222,646.19. This represents a 58.23% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 170,214 shares of company stock worth $17,548,337 over the last quarter. Insiders own 0.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on BSX shares. BTIG Research reiterated a “buy” rating and issued a $132.00 target price on shares of Boston Scientific in a report on Wednesday. Robert W. Baird boosted their price target on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 1st. Wells Fargo & Company boosted their price target on Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday. Weiss Ratings restated a “buy (b-)” rating on shares of Boston Scientific in a research note on Wednesday, October 8th. Finally, Evercore ISI restated an “outperform” rating on shares of Boston Scientific in a research note on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $123.77.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.